TABLE 3.

Haemophilus influenzae strain pairs from study participants who received macrolide(s) during the time that they carried H. influenzae (n = 27)

Study identifier	Strain first isolated	Strain last isolated	Multilocus ST	Strain duration (days)a	Rx no.b	Azithromycin MIC (μg/ml)
						Initial	Final
5	5P28H1	5P54H1c	103	819	4	2	16
13	13P24H2	13P36H1	57	355	1	2	2
19	19P49H1	19P94H1	243	1,422	5	1	2
24	24P44H4	24P45H1c	680	17	1	0.5	4
33	33P110H3	33P125H1	136	329	1	4	4
45	45P9H2	45P11H1	3	29	1	1	2
48	48P106H1	48P153H1	155	993	2	1	2
48	48P160H1	48P162H1	196	28	1	1	1
49	49P5H1	49P21H1	85	672	1	1	1
56	56P1H1	56P16H1	265	469	1	2	1
67	67P38H1	67P56H1c	156	570	2	1	4
67	67P10H5	67P50H1	411	1,380	1	1	1
73	73P2H1	73P39H1	14	1,175	1	4	4
84	84P18H1	84P20H1	66	77	1	4	4
87	87P128H2	87P138H1	389	140	2	4	4
91	91P109H1	91P114H1	98	70	1	1	0.5
91	91P3H3	91P4H1c	411	29	1	1	4
94	94P17H1	94P20H1	139	98	1	0.5	2
99	99P41H1	99P50H1	3	212	1	1	1
101	101P3H1	101P19H1	12	474	2	2	4
102	102P20H1	102P32H1c	159	364	1	0.5	4
103	103P3H1	103P20H1	155	565	2	1	0.5
107	107P50H1	107P75H1	215	560	7	2	4
122	122P4H1	122P13H1	11	254	1	2	4
126	126P11H1	126P26H1	66	344	1	0.5	2
128	128P1H1	128P56H1	98	932	3	2	4
138	138P2H1	138P39H1	203	721	1	1	2

^aStrain duration is defined as the number of days between the first date that the strain was identified and the last date that the strain was identified.

^bRx no., number of courses of macrolides administered while the strain was carried.

^cMIC of azithromycin increased 4-fold or more and reached or exceeded the CLSI breakpoint (≤4 μg/ml) during carriage.